HRMY today
$33.75-$0.47 (-1.37%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourBullish
15 minStrong Bullish
5 minLeaning Bearish
Daily trend turns up above $40.57
Key levels
Resistance$37.48
Resistance$34.11
Support$32.27
Support$29.96
Latest news & SEC filings
AnalystHC Wainwright reiterates Buy rating on Harmony Biosciences with $55 price target
EarningsHarmony Biosciences Holdings posts transcript of its third-quarter 2026 results call
EarningsHarmony Biosciences Posts Third-Quarter 2026 Numbers
All HRMY news →About Harmony Biosciences
Harmony Biosciences is a neuroscience pharmaceutical company developing therapies for rare neurological conditions. Its main commercial product is WAKIX (pitolisant), an oral medicine approved in the United States to treat excessive daytime sleepiness and sudden muscle weakness in people with narcolepsy. The company also has development programs in idiopathic hypersomnia, Prader-Willi syndrome, myotonic dystrophy type 1, rare epilepsies including Dravet and Lennox-Gastaut syndromes, and other neurobehavioral disorders. It sells through specialty distributors and pharmacies in the United States and holds rights to some products in Latin America.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
Harmony Biosciences Holdings, Inc. (HRMY)
What Is the Price Target for HRMY?
SEPT Low Target
$34.00
SEPT Mid Target
$50.00
SEPT High Target
$60.00
Analyst Consensus
$50.00
Is HRMY a Buy or Sell Right Now?
Thesis
- •Revenue growing 21.5% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for HRMY.
Start Free Trial →Is HRMY Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$48.75
66
Moat Score
NARROW
5/9
Piotroski Score
5.3
Altman Z-Score
What Is Smart Money Doing with HRMY?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Budur Kumar | officer | Buy | 10,406 | $319K | Sep 18, 2026 |
| Budur Kumar | officer | Buy | 25,446 | $770K | Sep 18, 2026 |
| Budur Kumar | officer | Sale | 35,852 | $1.5M | Sep 18, 2026 |
| Budur Kumar | officer | Buy | 400 | $12K | Sep 17, 2026 |
| Budur Kumar | officer | Sale | 800 | $34K | Sep 17, 2026 |
| Budur Kumar | officer | Buy | 900 | $28K | Sep 16, 2026 |
| Budur Kumar | officer | Sale | 1,800 | $77K | Sep 16, 2026 |
| Budur Kumar | officer | Buy | 18,750 | - | May 1, 2026 |
| Budur Kumar | officer | Sale | 8,882 | $283K | May 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →HRMY Growth Story
Revenue YoY
21.5%
3yr Revenue CAGR
25.6%
EPS Growth YoY
7.97%
FCF Growth YoY
59.1%
Revenue Trend
STRONG
Dark Pool Trades for HRMY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for HRMY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:59:51 | $34.12 | 1,100 | $$38K | SELL |
| 14:56:47 | $34.15 | 1,000 | $$34K | MIDPOINT |
| 14:56:47 | $34.15 | 1,100 | $$38K | MIDPOINT |
| 14:56:42 | $34.15 | 1,229 | $$42K | SELL |
| 14:52:11 | $34.17 | 2,200 | $$75K | MIDPOINT |
5 dark pool trades shown · $$226K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for HRMY
PREVIEWSEPT Investing provides real-time options flow tracking for HRMY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $55 | Dec 18 | 36 | $$10 | 1 | SWEEP |
| CALL | $50 | Dec 18 | 36 | $$15 | 1 | SWEEP |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Harmony Biosciences Holdings, Inc. (HRMY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →HRMY — frequently asked questions
What is HRMY stock price today?
Harmony Biosciences Holdings, Inc. (HRMY) is at $33.75, down 1.37% (-$0.47) at the Nov 12, 2026 close.
Why is HRMY stock moving today?
Latest HRMY news — Nov 12, 2026: HC Wainwright reiterates Buy rating on Harmony Biosciences with $55 price target · Nov 4, 2026: Harmony Biosciences Holdings posts transcript of its third-quarter 2026 results call
What is the HRMY price target?
The average analyst price target for HRMY is $50.00, ranging from $34 to $60, based on 6 analysts.
What do analysts rate HRMY?
Analyst ratings for HRMY: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did HRMY beat earnings?
HRMY last reported on Aug 4, 2026: EPS $1.28 vs $0.96 expected — a beat of 33.9%.
What is HRMY's P/E ratio?
HRMY trades at a P/E of 12.0 vs a Healthcare average of 17.7.
Does HRMY pay a dividend?
HRMY does not currently pay a dividend.
How much debt does HRMY have?
Harmony Biosciences Holdings, Inc. reported $154M of debt and $550M of cash (Jun 30, 2026).
What are HRMY support and resistance levels?
Support: $32.27, $29.96, $27.21. Resistance: $34.11, $37.48, $39.63.
What are insiders doing with HRMY?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on HRMY?
Nov 12, 2026: HC Wainwright reiterates Buy rating on Harmony Biosciences with $55 price target · Nov 4, 2026: Harmony Biosciences Holdings posts transcript of its third-quarter 2026 results call · Nov 4, 2026: Harmony Biosciences Posts Third-Quarter 2026 Numbers